A Phase 3 interventional study of JZP-110 and Placebo oral tablet in Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 60 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-23.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 7th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 120 across the 15 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once Daily Dosing
Drug: JZP-110
Once Daily Dosing
Drug: JZP-110
Once Daily Dosing
Drug: JZP-110
Once Daily Dosing
Drug: Placebo oral tablet
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12
Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing.
Time frame: Baseline to Week 12
Change in ESS Score From Baseline to Week 12
Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.
Time frame: Baseline to Week 12
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12
Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse
Time frame: Baseline to Week 12
Change in Sleep Latency Time on MWT Trial 1 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
Time frame: Change from baseline for sleep latency in MWT during trial 1 at week 12
Change in Sleep Latency Time on MWT Trial 2 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
Time frame: Change from baseline for sleep latency in MWT during trial 2 at week 12
Change in Sleep Latency Time on MWT Trial 3 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
Time frame: Change from baseline for sleep latency in MWT during trial 3 at week 12
Change in Sleep Latency Time on MWT Trial 4 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
Time frame: Change from baseline for sleep latency in MWT during trial 4 at week 12
Change in Sleep Latency Time on MWT Trial 5 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
Time frame: Change from baseline for sleep latency in MWT during trial 5 at week 12
Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4
Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from Baseline to Week 4.
Time frame: Baseline to Week 4
| Milestone | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 | Placebo |
|---|---|---|---|---|
| Started | 59 | 59 | 59 | 59 |
| Completed | 49 | 51 | 43 | 52 |
| Not completed | 10 | 8 | 16 | 7 |
Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 | 2.12 ± 1.289 | 4.74 ± 1.335 | 9.77 ± 1.327 | 12.27 ± 1.389 |
Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.
| points on a scale | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in ESS Score From Baseline to Week 12 | -1.6 ± 0.65 | -3.8 ± 0.67 | -5.4 ± 0.66 | -6.4 ± 0.68 |
Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse
| percentage of subjects | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12 | 39.7 | 67.8 | 78.2 | 84.7 |
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in Sleep Latency Time on MWT Trial 1 at Week 12 | -0.55 ± 4.658 | 3.27 ± 1.725 | 9.87 ± 1.713 | 9.91 ± 1.841 |
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in Sleep Latency Time on MWT Trial 2 at Week 12 | 1.41 ± 1.638 | 5.70 ± 1.697 | 9.46 ± 1.674 | 14.50 ± 1.835 |
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in Sleep Latency Time on MWT Trial 3 at Week 12 | 3.79 ± 1.799 | 6.35 ± 1.908 | 11.31 ± 1.859 | 13.99 ± 1.996 |
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in Sleep Latency Time on MWT Trial 4 at Week 12 | 2.33 ± 1.579 | 3.77 ± 1.663 | 9.77 ± 1.606 | 13.50 ± 1.734 |
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in Sleep Latency Time on MWT Trial 5 at Week 12 | 3.09 ± 1.808 | 3.92 ± 1.928 | 9.25 ± 1.888 | 12.20 ± 1.969 |
Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from Baseline to Week 4.
| minutes | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4 | 2.16 ± 1.202 | 4.67 ± 1.223 | 9.15 ± 1.246 | 13.07 ± 1.211 |
Collected over Through Week 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/59 (0%) | 0/59 (0%) | 17/59 (28.8%) |
| 75 mg of JZP-110 | 0/59 (0%) | 0/59 (0%) | 19/59 (32.2%) |
| 150 mg JZP-110 | 0/59 (0%) | 1/59 (1.7%) | 32/59 (54.2%) |
| 300 mg of JZP-110 | 0/59 (0%) | 0/59 (0%) | 36/59 (61%) |
| Event | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/59 | 0/59 | 1/59 | 0/59 |
| AnxietyPsychiatric disorders | 0/59 | 0/59 | 1/59 | 0/59 |
| Event | Placebo | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/59 | 6/59 | 14/59 | 18/59 |
| Decreased appetiteMetabolism and nutrition disorders | 1/59 | 5/59 | 5/59 | 9/59 |
| NasopharyngitisInfections and infestations | 3/59 | 5/59 | 8/59 | 3/59 |
| NauseaGastrointestinal disorders | 1/59 | 3/59 | 6/59 | 6/59 |
| Dry mouthGastrointestinal disorders | 2/59 | 3/59 | 4/59 | 6/59 |
| AnxietyPsychiatric disorders | 1/59 | 1/59 | 3/59 | 5/59 |
| Heart rate increasedInvestigations | 0/59 | 0/59 | 0/59 | 4/59 |
| Upper respiratory tract infectionInfections and infestations | 1/59 | 1/59 | 4/59 | 0/59 |
| Weight decreasedInvestigations | 0/59 | 1/59 | 1/59 | 3/59 |
| Weight increasedInvestigations | 3/59 | 2/59 | 0/59 | 1/59 |
| Age, Continuous(years) | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 36.5 ± 12.78 | 38.1 ± 13.00 | 34.3 ± 11.51 | 36.0 ± 15.17 | 36.3 ± 12.47 |
| Sex: Female, Male(Participants) | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 37 | 42 | 40 | 35 | 154 |
| Male | 22 | 17 | 19 | 24 | 82 |
| Race (NIH/OMB)(Participants) | 75 mg of JZP-110 | 150 mg JZP-110 | 300 mg of JZP-110 | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 2 |
| Asian | 0 | 3 | 3 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 12 | 6 | 5 | 10 | 33 |
| White | 46 | 48 | 48 | 47 | 189 |
| More than one race | 1 | 1 | 1 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2015 to primary completion in Feb 2017, 21 months.
Results were first posted in Jul 2019, 2 years 5 months after primary completion. A results delay was requested in Jan 2018.
Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solriamfetol